W
Walter Berger
Researcher at Medical University of Vienna
Publications - 396
Citations - 16667
Walter Berger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 63, co-authored 359 publications receiving 14045 citations. Previous affiliations of Walter Berger include University of Vienna & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds.
Christian R. Kowol,Petra Heffeter,Walter Miklos,Lars Gille,Robert Trondl,Loredana Cappellacci,Walter Berger,Bernhard K. Keppler,Bernhard K. Keppler +8 more
TL;DR: Thiol-induced intracellular ROS generation might contribute to the anticancer activity of copper thiosemicarbazone complexes but is not the determining factor, while experiments on generation of oxidative stress and the influence of biologically relevant reductants revealed that reductant-dependent redox cycling occurred mainly outside the cells.
Journal ArticleDOI
Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells.
R. Dornetshuber,Petra Heffeter,Majidreza Kamyar,Thomas Peterbauer,Walter Berger,Rosa Lemmens-Gruber +5 more
TL;DR: The results suggest that short-term exposure to very low ENN concentrations, for example, via food intake, might have tumor-promoting functions based on growth stimulation, suggesting a potential quality of ENN as an anticancer drug.
Journal ArticleDOI
Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas.
Gwendoline Van Goietsenoven,Jenna Hutton,Jean-Paul Becker,Benjamin Lallemand,Francis Robert,Florence Lefranc,Christine Pirker,Guy Vandenbussche,Pierre Van Antwerpen,Antonio Evidente,Walter Berger,Martine Prévost,Jerry Pelletier,Robert Kiss,Terri Goss Kinzy,Alexander Kornienko,Véronique Mathieu +16 more
TL;DR: In this paper, the eEF1A targeting with narciclasine (50 nM) leads to marked actin cytoskeleton disorganization, resulting in cytokinesis impairment, and protein synthesis impairment (elongation and initiation steps), whereas apoptosis is induced at higher doses only (≥200 nM).
Journal ArticleDOI
Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action
Maria V. Babak,Maria V. Babak,Samuel M. Meier,Kilian Huber,Jóhannes Reynisson,Anton A. Legin,Michael A. Jakupec,Alexander Roller,Alexey Stukalov,Manuela Gridling,Keiryn L. Bennett,Jacques Colinge,Walter Berger,Paul J. Dyson,Giulio Superti-Furga,Bernhard K. Keppler,Christian G. Hartinger +16 more
TL;DR: In this paper, the authors employed a chemical proteomic approach to identify the molecular targets of an antimetastatic ruthenium organometallic complex based on 1,3,5-triaza-7phosphaadamantane (RAPTA).
Journal ArticleDOI
Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Hedwig Sutterlüty,Christoph-Erik Mayer,Ulrike Setinek,Johannes Attems,Slav Ovtcharov,Mario Mikula,Wolfgang Mikulits,Michael Micksche,Walter Berger +8 more
TL;DR: The results suggest that Spry2 plays a role as tumor suppressor in NSCLC by antagonizing receptor tyrosine kinase–induced signaling at different levels, indicating feasibility for the usage of Spry in targeted gene therapy of NSCLCs.